1 CR from the first and only clinical trial update on low dosage released 16 months a. If it wasn't excellent then the pps wouldn't have re-rate from 4c t0 15c with over 2B shares traded and the FDA wouldn't have granted Fast Track designation within only 16 months of clinical trial. And that's why the pps is cheap right now as the market hasn't value any of the fundamental achievement in the last 16 months from VAXINIA and Azer-Cel.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |